VXA-221

VXA-221 is a bispecific antibody-drug conjugate (BsADC) currently in the discovery phase, developed by **VERAXA Biotech**. The therapeutic is being developed for the treatment of solid tumors, specifically targeting **lung cancer** and **breast cancer**. VXA-221 is engineered using VERAXA's proprietary microfluidic screening and site-specific "click-chemistry" conjugation platform. This technology is designed to produce ADCs with precise drug-to-antibody ratios (DAR) and high stability, potentially improving the therapeutic index compared to traditional conjugation methods. As a bispecific agent, VXA-221 is intended to bind two distinct antigens or epitopes, which may enhance tumor selectivity, increase internalization rates, and mitigate resistance mechanisms common in monospecific ADC therapies.